BMY BRISTOL MYERS SQUIBB CO

NYSE bms.com


$ 43.60 $ 0.24 (0.55 %)    

Friday, 17-Oct-2025 19:29:34 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 43.63
$ 43.26
$ 43.55 x 101
$ 43.64 x 100
$ 43.11 - $ 43.66
$ 42.38 - $ 61.00
13,796,411
na
88.81B
$ 0.30
$ 17.59
TBD
na
na ($ 0.06)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-31-2025 06-30-2025 10-Q
2 04-24-2025 03-31-2025 10-Q
3 02-12-2025 12-31-2024 10-K
4 10-31-2024 09-30-2024 10-Q
5 07-26-2024 06-30-2024 10-Q
6 04-25-2024 03-31-2024 10-Q
7 02-13-2024 12-31-2023 10-K
8 10-26-2023 09-30-2023 10-Q
9 07-27-2023 06-30-2023 10-Q
10 04-27-2023 03-31-2023 10-Q
11 02-14-2023 12-31-2022 10-K
12 10-26-2022 09-30-2022 10-Q
13 07-27-2022 06-30-2022 10-Q
14 04-29-2022 03-31-2022 10-Q
15 02-09-2022 12-31-2021 10-K
16 10-27-2021 09-30-2021 10-Q
17 07-28-2021 06-30-2021 10-Q
18 04-29-2021 03-31-2021 10-Q
19 02-10-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-06-2020 06-30-2020 10-Q
22 05-07-2020 03-31-2020 10-Q
23 02-24-2020 12-31-2019 10-K
24 10-31-2019 09-30-2019 10-Q
25 07-25-2019 06-30-2019 10-Q
26 04-25-2019 03-31-2019 10-Q
27 02-25-2019 12-31-2018 10-K
28 10-25-2018 09-30-2018 10-Q
29 07-26-2018 06-30-2018 10-Q
30 04-26-2018 03-31-2018 10-Q
31 02-13-2018 12-31-2017 10-K
32 10-26-2017 09-30-2017 10-Q
33 07-27-2017 06-30-2017 10-Q
34 04-27-2017 03-31-2017 10-Q
35 02-21-2017 12-31-2016 10-K
36 10-27-2016 09-30-2016 10-Q
37 07-28-2016 06-30-2016 10-Q
38 04-28-2016 03-31-2016 10-Q
39 02-12-2016 12-31-2015 10-K
40 10-27-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 bristol-myers-squibb-systimmune-present-oral-safety-efficacy-results-from-global-phase-1-us-lung-101-trial-of-iza-bren-to-treat-advanced-solid-tumors-data-revealed-promising-antitumor-activity-across-different-tumor-types-manageable-safety-profile

REDMOND, Wash. and PRINCETON, N.J., Oct. 17, 2025 /PRNewswire/ -- SystImmune Inc. (SystImmune), a clinical-stage biotechnology ...

 bristol-myers-squibb-and-insitro--announced-the-next-phase-of-their-collaboration-to-discover-new-molecules-with-potential-as-new-treatments-for-amyotrophic-lateral-sclerosis-collaboration-extension-builds-on-5-year-agreement-announced-in-2020

insitro, a pioneer in machine learning–driven drug discovery and development, and Bristol Myers Squibb (NYSE:BMY), today announ...

 bristol-myers-squibb-to-present-data-from-over-50-oncology-studies-at-esmo-congress-2025-covering-over-10-cancer-types-across-pipeline-and-portfolio

Bristol Myers Squibb (NYSE:BMY) today announced the presentation of data across its oncology portfolio and pipeline at the Euro...

 systimmune-announced-first-patient-dosed-in-ph23-izabright-breast01-trial-of-iza-bren-in-previously-untreated-triple-negative-breast-cancer-250m-milestone-payment-triggered-from-bristol-myers-squibb

SystImmune, Inc., a clinical-stage biotechnology company, today announced the treatment of the first patient in the IZABRIGHT-B...

 bristol-myers-expands-cell-therapy-portfolio-with-orbital-therapeutics-acquisition

Bristol Myers Squibb is acquiring Orbital Therapeutics for $1.5 billion, expanding its RNA and in vivo CAR T-cell therapy portf...

 bristol-myers-squibb-agreed-to-acquire-orbital-therapeutics-a-privately-held-biotechnology-for-15b

Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with po...

 these-3-pharma-stocks-are-rallying--and-still-trade-absurdly-cheap

Health care stocks are rallying, but Pfizer, Merck and Bristol-Myers still trade below 10x forward P/E — a rare market discount.

 health-care-stocks-rally-nike-beats-the-street-whats-moving-markets-wednesday

Wall Street posts modest gains as shutdown begins and jobs data disappoints, but optimism around earnings and rate cuts keeps m...

 trumps-100-drug-tariffs-a-meaningful-commercial-hit-for-americans-but-loopholes-could-blunt-impact-says-analyst

President Donald Trump‘s proposed 100% tariffs on pharmaceuticals could have a smaller impact than initially expected, thanks t...

 trumps-100-pharmaceutical-tariff-the-270-billion-manufacturing-war-that-could-reshape-your-medicine-cabinet

Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creatin...

 bristol-myers-to-sell-its-pill-for-psoriasis-directly-to-cash-paying-patients--at-80-discount-to-the-drugs-list-price-following-president-donald-trumps-demand

https://www.bloomberg.com/news/articles/2025-09-25/bristol-to-sell-psoriasis-pill-for-80-off-after-trump-demand

 bristol-myers-squibb-franchise-gains-momentum-with-phase-3-results-in-multiple-myeloma-patients

Bristol Myers Squibb reported positive Phase 3 results for iberdomide in multiple myeloma; analysts eye CELMoDs as key to futur...

 bristol-myers-plans-uk-launch-of-schizophrenia-drug-cobenfy-matching-us-price--reuters

https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myers-plans-launch-schizophrenia-drug-uk-list-price-equal-u...

Core News & Articles

For next-generation CRM with deep, industry-specific AI agentsPLEASANTON, Calif., Sept. 22, 2025 /PRNewswire/ -- Veeva Systems ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION